Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 ...

This was the stock's third consecutive day of gains.

Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 ...

Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the ...